D. van der Biessen

Early cessation of the clinical development of LiPlaCis, a liposomal cisplatin formulation

Maja J.A. de Jonge, Marije Slingerland, Walter J. Loos et al. · European Journal of Cancer · 2010 · 90 citations

Lipid Preparation, Early Cessation, Liposomal Cisplatin Formulation +4

Phase I dose-escalation study of F60008, a novel apoptosis inducer, in patients with advanced solid tumours

Jos Kitzen, Maja J.A. de Jonge, C. B. H. W. Lamers et al. · European Journal of Cancer · 2009 · 88 citations

Medicine, Apoptosis, Cell Death +8

Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor

Paul Hamberg, Margaret M. Woo, Lin‐Chi Chen et al. · Cancer Chemotherapy and Pharmacology · 2011 · 44 citations · Full text

Phase I study of olaparib in combination with carboplatin and/or paclitaxel in patients with advanced solid tumors.

Ruud van der Noll, Joo Ern Ang, Agnes Jager et al. · Journal of Clinical Oncology · 2013 · 34 citations

Brca1/2 Mutation, Medicine, Continuous O +15

Impact of pazopanib on docetaxel exposure: results of a phase I combination study with two different docetaxel schedules

Paul Hamberg, Ron H.J. Mathijssen, Peter de Bruijn et al. · Cancer Chemotherapy and Pharmacology · 2014 · 23 citations

Drug Safety, Pharmacology, Different Docetaxel Schedules +8